Loading...
Most people with HIV are treated with antiretroviral regimens that combine several medicines into a single pill. However, people with drug-resistant HIV often take complex regimens consisting of multiple pills with medications from different drug classes.
In a new industry-supported trial, researchers studied a simplified regimen for this latter group — a novel, single-tablet, oral treatment combining bictegravir, a widely used integrase inhibitor, and lenacapavir, an HIV capsid inhibitor. Over 550 people with virologic suppression on complex regimens were randomly assigned to switch to bictegravir/lenacapavir or to continue their complex regimen. At baseline, participants had been on HIV treatment for roughly 28 years and were taking…